A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

NCT02057341

Last updated date
Study Location
Stanford University School of Medicine
Stanford, California, 94305, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
LMNA-Related Dilated Cardiomyopathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with idiopathic dilated cardiomyopathy and stable New York Heart Association (NYHA) Class II - IIIa congestive heart failure (CHF).

- Stable, guidelines-based medical and device therapy, without any CHF hospitalizations or change in heart failure drug dose with ≥ 50% reduction in dose or ≥ 100% increase in dose in the past 3 months.

- Left ventricular (LV) end diastolic diameter by trans-thoracic echocardiography of > 3.3 cm/m2 (for females) or 3.4 cm/m2 (for males) and/or LV ejection fraction ≤ 45%.

- Gene positive for a pathogenic mutation in the LMNA gene, as determined by a CLIA-certified clinical laboratory (mutations including but not limited to: splice-site, non-sense, deletion mutations, a mis-sense mutation in a highly conserved codon, a mis-sense mutation involving a major charge change, a mis-sense mutation previously associated with genetic dilated cardiomyopathy).

- Within 3 weeks prior to first dose of study drug, completed distance during six minute walk test of ≥ 100 m and ≤ 350 m AND/OR ≥ 100 m and ≤ 450 m AND ≤ 60% predicted distance AND patient is symptomatic for dilated cardiomyopathy per Investigator judgment.

- On the day before and day of first dose of study drug, completed distance during six minute walk test of ≥ 100 m and ≤ 400 m (with the greater value within 10% of the lesser value) AND/OR ≥ 100 m and ≤ 475 m (with the greater value within 10% of the lesser value) AND patient is symptomatic for dilated cardiomyopathy per Investigator judgment.

- Acceptable hematology, hepatic and renal function laboratory values within 3 weeks prior to first dose of study drug.

- Additional criteria exist.

Key

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Unstable clinical cardiac symptoms requiring unscheduled hospitalization within 60
days prior to study start.


- Clinically significant coronary artery disease, as per Investigator judgment.


- Currently receiving continuous intravenous (IV) inotrope infusion, or presence of a
ventricular assist device, or history of prior heart transplantation.


- Any of the following within 60 days prior to study start: Myocardial infarction,
cardiac surgical procedures, acute coronary syndrome, hemodynamically destabilizing
cardiac arrhythmia, serious systemic infection with evidence of septicemia, any major
surgical procedure requiring general anesthesia.


- Uncorrected, hemodynamically significant primary valvular disease.


- Initiation of cardiac resynchronization therapy within 180 days prior to study start.


- Likelihood, in the Investigator's opinion, of undergoing cardiac transplantation, left
ventricular assist device or other device implantation, or other cardiac surgery
within the next 6 months; or of requiring continuous IV inotropic treatment, or
referral for hospice or end-of-life treatment.


- Active malignancy (except surgically-curative basal cell carcinoma, squamous cell
carcinoma, or cervical carcinoma).


- Receiving chronic immunosuppressant therapy.


- Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B
and/or hepatitis C.


- Participation in any other investigational study of drugs or devices within 30 days
prior to study start.


- Additional criteria exist.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

LMNA-Related Dilated CardiomyopathyA Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
NCT02057341
  1. Stanford, California
  2. Aurora, Colorado
  3. Baltimore, Maryland
  4. Boston, Massachusetts
  5. Columbus, Ohio
  6. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
LMNA-Related Dilated CardiomyopathyA Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
NCT02351856
  1. Aurora, Colorado
  2. Baltimore, Maryland
  3. Boston, Massachusetts
  4. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Official Title  ICMJE Not Provided
Brief Summary This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the drug's safety. Approximately 12 patients from the US will be enrolled in this study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE LMNA-Related Dilated Cardiomyopathy
Intervention  ICMJE Drug: ARRY-371797, p38 inhibitor; oral
multiple dose, single schedule
Study Arms  ICMJE
  • Experimental: ARRY-371797 (Dose 1)
    Intervention: Drug: ARRY-371797, p38 inhibitor; oral
  • Experimental: ARRY-371797 (Dose 2)
    Intervention: Drug: ARRY-371797, p38 inhibitor; oral
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 5, 2014)
12
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2016
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Patients with idiopathic dilated cardiomyopathy and stable New York Heart Association (NYHA) Class II - IIIa congestive heart failure (CHF).
  • Stable, guidelines-based medical and device therapy, without any CHF hospitalizations or change in heart failure drug dose with ? 50% reduction in dose or ? 100% increase in dose in the past 3 months.
  • Left ventricular (LV) end diastolic diameter by trans-thoracic echocardiography of > 3.3 cm/m2 (for females) or 3.4 cm/m2 (for males) and/or LV ejection fraction ? 45%.
  • Gene positive for a pathogenic mutation in the LMNA gene, as determined by a CLIA-certified clinical laboratory (mutations including but not limited to: splice-site, non-sense, deletion mutations, a mis-sense mutation in a highly conserved codon, a mis-sense mutation involving a major charge change, a mis-sense mutation previously associated with genetic dilated cardiomyopathy).
  • Within 3 weeks prior to first dose of study drug, completed distance during six minute walk test of ? 100 m and ? 350 m AND/OR ? 100 m and ? 450 m AND ? 60% predicted distance AND patient is symptomatic for dilated cardiomyopathy per Investigator judgment.
  • On the day before and day of first dose of study drug, completed distance during six minute walk test of ? 100 m and ? 400 m (with the greater value within 10% of the lesser value) AND/OR ? 100 m and ? 475 m (with the greater value within 10% of the lesser value) AND patient is symptomatic for dilated cardiomyopathy per Investigator judgment.
  • Acceptable hematology, hepatic and renal function laboratory values within 3 weeks prior to first dose of study drug.
  • Additional criteria exist.

Key Exclusion Criteria:

  • Unstable clinical cardiac symptoms requiring unscheduled hospitalization within 60 days prior to study start.
  • Clinically significant coronary artery disease, as per Investigator judgment.
  • Currently receiving continuous intravenous (IV) inotrope infusion, or presence of a ventricular assist device, or history of prior heart transplantation.
  • Any of the following within 60 days prior to study start: Myocardial infarction, cardiac surgical procedures, acute coronary syndrome, hemodynamically destabilizing cardiac arrhythmia, serious systemic infection with evidence of septicemia, any major surgical procedure requiring general anesthesia.
  • Uncorrected, hemodynamically significant primary valvular disease.
  • Initiation of cardiac resynchronization therapy within 180 days prior to study start.
  • Likelihood, in the Investigator's opinion, of undergoing cardiac transplantation, left ventricular assist device or other device implantation, or other cardiac surgery within the next 6 months; or of requiring continuous IV inotropic treatment, or referral for hospice or end-of-life treatment.
  • Active malignancy (except surgically-curative basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma).
  • Receiving chronic immunosuppressant therapy.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
  • Participation in any other investigational study of drugs or devices within 30 days prior to study start.
  • Additional criteria exist.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02057341
Other Study ID Numbers  ICMJE ARRAY-797-231
C4411004 ( Other Identifier: Pfizer )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP